Docetaxel Retinopathy: A Case Report

Nghiem-Buffet, Sylvia; Cohen, Salomon Y.; Giocanti-Aurégan, Audrey

doi:10.1159/000455088

Cited by 12 publications

(6 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding retinal adverse effects, there have been several cases of docetaxel-related maculopathy associated with other agents or conditions that potentiate maculopathy. 33–36 However, in our cohort of 371 patients taking docetaxel, none were diagnosed with cystoid macular edema by an eye care provider. Of 1533 patients taking paclitaxel, 4 (0.3%) developed related cystoid macular edema.…”

Section: Discussionmentioning

confidence: 80%

Ophthalmic adverse effects of taxanes: The Mayo Clinic experience

Fortes

Liou

Dalvin

2020

European Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose: To investigate ophthalmic side effects of taxanes and compare side effect frequency, requirement for cessation of taxane therapy, visual acuity outcome, and concurrent systemic effects between paclitaxel and docetaxel. Methods: Patients taking taxanes at a single center from 1/1/2010 to 2/29/2020 were retrospectively reviewed for clinical characteristics, treatments, and concurrent systemic adverse effects. Results: Of 1918 patients, 22 (1.1%) experienced an ophthalmic side effect that came to the attention of an eye care provider. Mean age at presentation of the side effect was 62 years (median 66, range 23–82). The most common side effect was meibomian gland dysfunction in 5 (23%) patients, followed by cystoid macular edema in 4 (18%) patients and canalicular obstruction in 4 (18%) patients, followed by diplopia in 2 (9%) patients, and singular cases of lash alopecia, and blepharitis, among others. Lids/lashes as well as nasolacrimal duct adverse effects occurred more frequently with docetaxel therapy than with paclitaxel therapy. Follow-up was available in 10 (45%) patients, with mean duration of 5 months (median 4, range 0–12 months). Of these patients, the ophthalmic side effects were resolved or controlled without discontinuing therapy in 8 (80%) patients. Taxane cessation was required in one patient with docetaxel-related canalicular obstruction and one patient with paclitaxel-related cystoid macular edema. Conclusion: Ophthalmic taxane-related adverse events are rare with estimated frequency of ophthalmic side effects of about 1%. Nevertheless, it is important that ophthalmologists recognize the range of side effects for optimal management. Most ophthalmic events can be treated with targeted therapy without discontinuation of life-prolonging taxane therapy.

show abstract

Section: Discussionmentioning

confidence: 80%

Ophthalmic adverse effects of taxanes: The Mayo Clinic experience

Fortes

Liou

Dalvin

2020

European Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…Taxane-induced CME has been reported with 4 cases involving docetaxel,2, 3, 4, 5 but previous case reports have been clouded by the concurrent use of other agents (such as tamoxiphen) or conditions (retinitis pigmentosa or the fluid retention syndrome) also known to cause CME. This has led some to hypothesize that taxanes might potentiate the tendency towards CME in such settings 4 , 5 . Generally, the CME resolved with cessation of the drug, although in some cases topical or oral acetazolamide was also used 2 , 6 .…”

Section: Discussionmentioning

confidence: 99%

“…Their mechanism of action is to disrupt the function of the microtubules by binding to beta-tubulin subunit stabilizing microtubules, inhibiting cell replication, and inducing apoptosis 8 . Reported ocular adverse effects of docetaxel are rare but include canalicular stenosis, toxic optic neuropathy, conjunctivitis, and non-leaking cystoid macular degeneration 2, 3, 4, 5 , 9, 10, 11. One member of the taxane class of drugs, paclitaxel, is reported to be more toxic than docetaxel, possibly related to its more quickly achieving a cumulative dose needed to induce CME 6 , 12 , 13 …”

Section: Discussionmentioning

confidence: 99%

“…In fact, the rationale for using carbonic anhydrase inhibitors is to enhance RPE pumping function 21 , 24 , 25 . Whatever the exact mechanism, taxanes could potentiate the (non-leaking) CME effect of other agents (like tamoxifen 5 , 12 or HCQ) at the level of the RPE pump as was suggested by Buffet et al 5 The occurrence of CME in a retinitis pigmentosa patient also supports the possibility of RPE dysfunction as a possible mechanism triggered or compounded by the taxane effect 4 …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Docetaxel-induced maculopathy possibly potentiated by concurrent hydroxychloroquine use

Elhusseiny

Relhan

Smiddy

2019

American Journal of Ophthalmology Case Reports

View full text Add to dashboard Cite

PurposeTo report a case of bilateral non-leaking cystoid macular degeneration induced by docetaxel, possibly potentiated by hydroxychloroquine.ObservationsA 63-year-old female patient with a long-term history of rheumatoid arthritis controlled on hydroxychloroquine for 33 years with no evidence of retinopathy developed bilateral loss of vision after having been on docetaxel chemotherapy for breast cancer. Optical coherence tomography showed bilateral cystic maculopathy with no angiographic evidence of leakage on fluorescein angiography. The patient was treated conservatively with no further interventions. Marked improvement of the macular degeneration occurred over the subsequent 9 months, but without visual improvement, although a cataract likely confounded final visual acuity measurement.Conclusions and importanceDocetaxel-induced maculopathy has been previously reported, but with only four case reports in literature, and most often in conjunction with concurrent therapies or conditions also known to cause macular edema. This is the first case report of docetaxel-induced maculopathy in a setting of hydroxychloroquine therapy which may possibly has potentiated the effect of docetaxel to induce maculopathy. Impaired transcellular retinal pigment epithelial transport might be the cause of non-leaking cystic maculopathy.

show abstract

“…Eye disorders, such as watering eyes (epiphora), lacrimal duct obstruction, and cystoid macular edema, have also been reported. [10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28] Watering eyes and lacrimal duct obstruction have been frequently reported. [10][11][12][13][14][15][16][17][18][19][20] Intravenously administered DTX is distributed to the tear fluid from the plasma.…”

Section: Introductionmentioning

confidence: 99%

Current status of eye disorders caused by docetaxel administration every 3 weeks: A case-control study in Japanese patients

Noguchi

Kawashima²,

Maruyama³

et al. 2019

J Oncol Pharm Pract

View full text Add to dashboard Cite

Purpose Docetaxel is known to cause eye disorders. In this study, current status of eye disorders caused by docetaxel administration every 3 weeks in Japanese patients was examined. Methods This case-control study targeted patients who were newly administered docetaxel at the Kyoto Okamoto Memorial Hospital between 1 July 2015 and 30 June 2018. Eye disorder occurrence was defined as an event in which the pharmacist confirmed the symptoms in a patient interview and the ophthalmologist diagnosed the disorder. Results Of the 89 subjects, 7 (7.9%) had eye disorders. The symptoms were watering eyes (7.9%), a stye and eye discharge (2.2% each), corneal and conjunctival disorder, visual acuity reduction, and blepharedema (1.1% each). Four patients who presented with watering eyes, eye discharge, or corneal and conjunctival disorder showed improvement with the use of eye drops such as artificial tears. Two patients who presented with a stye showed improvement with the use of oral cefcapene. One patient with mild symptoms showed spontaneous improvement. However, one patient had irreversible visual acuity reduction. The multivariate logistic regression analysis revealed that a cumulative docetaxel dose of ≥300 mg/m2 (odds ratio: 15.50, 95% confidence interval: 1.37–175.00, p = 0.027) and concomitant cyclophosphamide use (odds ratio: 13.20, 95% confidence interval: 1.13–153.00, p = 0.039) were significant risk factors associated with eye disorders. Conclusion In conclusion, it was determined that docetaxel-related eye disorders might be influenced by the cumulative dose of docetaxel and concomitant cyclophosphamide use. In addition, relatively mild symptoms improved with medication.

show abstract

Docetaxel Retinopathy: A Case Report

Cited by 12 publications

References 14 publications

Ophthalmic adverse effects of taxanes: The Mayo Clinic experience

Ophthalmic adverse effects of taxanes: The Mayo Clinic experience

Docetaxel-induced maculopathy possibly potentiated by concurrent hydroxychloroquine use

Current status of eye disorders caused by docetaxel administration every 3 weeks: A case-control study in Japanese patients

Contact Info

Product

Resources

About